Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results i
 

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

More...